Share
clock Created with Sketch. 07/06/25
23:53
Share
Originally posted by Silverchair:
↑
FY2022 $20.9 Million NPAT . FY2023 $30.6 Million NPAT . FY2024 $35.6 Million NPAT . FY2025 we don't know yet but just adding last years 2nd half to this years 1st half would give about $40 Million NPAT ? They are printing cash at ever growing rates.and further positive news about the 'spontaneous repigmentation' some patients achieved after therapy. Further info of expecting to see 9% penetration in target market for total 5931 patients in Yrs 1-2. That exciting potential figure again of $490 - $570 Million USD. ($750 Million to $880 Million AUD). Vitiligo if approved will be a massive event for Clinuvel and patients alike. Treatment centres are ready to go (and the number is growing all the time), billing codes and already established distribution channels with no 'middle man' to share profits with or Big pharma.
Expand
One thing I can't understand is why CUV has never made a significant investment with their cash. It hasn't shrunk (at least on a half-yearly basis) since their first revenues, and their management keeps stressing how fiscally responsible they are. Their cash stockpile would make sense if CUV were serious about launching Scenesse for vitiligo themselves.
(20min delay)